The ErbB-4 receptor tyrosine kinase has a PDZ domain recognition motif at its carboxyl terminus. The first step in ErbB-4 proteolytic processing is a metalloprotease-dependent cleavage of the receptor ectodomain, which is not influenced by deletion of this motif. Metalloprotease cleavage of ErbB-4 produces a membrane-associated 80-kDa fragment that is a substrate for subsequent γ-secretase cleavage, which releases the cytoplasmic domain from the membrane and allows nuclear translocation of this fragment. Deletion of the PDZ domain recognition motif does abrogate the γ-secretase cleavage of ErbB-4. The wild-type 80-kDa ErbB-4 fragment forms an association complex with presenilin, thought to be the catalytic moiety of γ-secretase activity. However, this association is significantly impaired by loss of the PDZ domain recognition motif from ErbB-4. Deletion of this ErbB-4 motif prevents the nuclear localization of the ErbB-4 cytoplasmic domain. Data also show that the basal cleavage of wild-type ErbB-4 by this proteolytic system can produce a sufficient level of ErbB-4 processing to negatively influence cell growth and that loss of the PDZ domain recognition motif abrogates this response.

ErbB-4 is a type I receptor tyrosine kinase that binds heregulin (HRG)1 (1). HRG also binds to ErbB-3. In addition some ErbB-1 ligands (heparin-binding epidermal growth factor, betacellulin, and epiereguin) are reported to activate ErbB-4.

Recently, ErbB-4 was shown to be processed by a novel proteolytic pathway (2), analogous to that which generates cell fate determination responses after activation of the Notch non-tyrosine kinase receptor (3). The amyloid precursor protein (APP) is also processed in a similar manner (4). The first step in this pathway is cleavage within the ectodomain close to the plasma membrane. In the case of ErbB-4, this cleavage is stimulatable by TPA (5) and, in some cell lines, by HRG (6). This proteolytic event results in the release of a 120-kDa ErbB-4 fragment into the extracellular milieu and the cellular retention of an 80-kDa membrane-associated fragment. Ectodomain cleavage requires the transmembrane metalloprotease tumor necrosis factor-α-converting enzyme (7).

After ectodomain cleavage of ErbB-4, the cell-associated 80-kDa fragment containing the transmembrane and cytoplasmic domains is cleaved by a γ-secretase activity releasing the cytoplasmic domain into the cytosol (2, 8). Subsequently, the cytoplasmic domain fragment of ErbB-4 translocates into the nucleus. The function of the 80-kDa fragment in the nucleus is not known, although the carboxyl-terminal region of this fragment does display weak activity in the GAL4 transcription activation assay (2). Importantly, γ-secretase inhibitors block the induction of cell death by HRG when T47D carcinoma cells are placed in serum-free media (2). The nuclear localization of other receptor tyrosine kinases, including ErbB-1 (9), ErbB-3 (10), and fibroblast growth factor receptor 1 (11), have been described, but these do not appear to involve proteolytic processing of the receptors.

At this time relatively little is known about how transmembrane metalloprotease tumor necrosis factor-α-converting enzyme and γ-secretase recognize their substrates. In this study, evidence is provided that ErbB-4 PDZ domain recognition motif is necessary for γ-secretase cleavage.

**EXPERIMENTAL PROCEDURES**

**Materials**—HRG β1 was purchased from R&D Systems. The cDNA for human ErbB-4 and rabbit antisera to a carboxyl-terminal sequence (residues 1108–1264) of human ErbB-4 was generously provided by Dr. Matthias Kraus (University of Alabama, Birmingham, AL) and used for Western blotting. Polyclonal antibodies C-18 to an epitope in the carboxyl terminus of ErbB-4 and H-70 to an epitope in the amino terminus of presenilin 1 were obtained from Santa Cruz Biotechnology. Monoclonal anti-phosphotyrosine antibody (13-9000) and horseradish peroxidase-conjugated Protein A were purchased from Zymed Laboratories Inc. Protein A-Sepharose CL-4B, enhanced chemiluminescence (ECL) reagents, and TPA were obtained from Sigma. The γ-secretase inhibitor Compound E (12) was provided by Dr. Todd Golde (Mayo Clinic, Jacksonville, FL). Nuclear export signal inhibitor leptomycin B was provided by Dr. Minoru Yoshida (University of Tokyo, Japan). G418 sulfate was obtained from Mediatech Inc. All other chemicals were reagent grade from Sigma.

**Cell Culture**—COS7 and NIH3T3 cell lines were obtained from American Tissue Culture Collection. These cells and all NIH3T3-derived cells, described below, were routinely grown in 5% CO2 at 37 °C in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (FBS) and penicillin/streptomycin (Mediatech Inc.). Experimental cultures were generally grown in 100-mm culture dishes until 90% confluence unless otherwise noted in the text.

**Gene Transfection and Establishment of ErbB-4 Wild-type (WT) and ΔTVV Cell Lines**—LTR-W.T.ErbB4 is an ErbB-4 expression vector under the control of a LTR promoter and is described elsewhere (13). It contains a neomycin selection marker. To produce a cDNA construct to express ErbB-4 with the carboxyl-terminal three residues TVV truncated, an 18-mer upstream primer, 5′-GACATCCTCCAGGAGTAC-3′, was synthesized to match a sequence within ErbB-4 cDNA containing a BamHI site. Also, a 31-mer downstream primer 5′-ACCGGTGACT-TAATTCCGCTAGCTGAAG-3′, was made containing a SalI site next to stop code TAA, which terminates translation 9 bp before the wild-type ErbB-4 stop sequence. ICR amplification of LTR-W.T.ErbB4 cDNA with the above primers produced a 166-bp fragment that was then cut with BamHI and SalI to generate cohesive ends. The LTR-W.T.ErbB4 construct was processed to remove the small fragment.
between BamHI and SalI (next to the stop-codon), and the PCR product was inserted into the exact site. The resulting construct, called LTR-ΔTVV, contains ErbB-4 cDNA with 9 bp corresponding to the carboxy-terminal three residues, i.e. TVV, deleted. The mutant construct was verified by enzymatic digestion and DNA sequencing.

For gene transfection, COS7 and NIH3T3 cells were transfected with LTR-WT-ErbB4 or LTR-ΔTVV using Effectene reagent (Qiagen) according to the manufacturer’s protocol. Typically, 2.0–2.5 μg of DNA was used to transfect cells in a 100-mm dish. COS7 cells were assayed for ErbB-4 receptor function 36–48 h after transfection. Stably transfected NIH3T3 cell lines were obtained after selection in G418 sulfate (400 μg/ml) for 2 months. Each stably transfected cell line, either WT ErbB-4 or ΔTVV mutant, represents a pool of several individual colonies for each receptor species, two stably transfected cell lines from independent transfections were established and assayed.

**Cell Treatment and Lysis and Fractionation**—Cell lysates were obtained essentially as described previously (5) with some modifications. Briefly, 90% confluent cell monolayers in 100 mm dishes were incubated overnight in DMEM containing 0.2% FBS (or 1% FBS, as indicated in the text). Cells were then incubated at 37 °C with the indicated additions for the indicated times. Next, the cells were washed three times with Ca2+/Mg2+-free phosphate-buffered saline (Ca2+/Mg2+-free PBS) and lysed in 1 ml of cold TGH lysis buffer (1% Triton X-100, 10% glycerol, 20 mM Hepes (pH 7.2), 100 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 10 μg/ml leupeptin, 1 mM Na3VO4, and 50 μg/ml NaF) or mild TGH lysis buffer, having reduced levels of Triton X-100 (0.2%) and NaCl (20 mM). The lysed cells were scraped from the dish and placed in a 1.5-ml microcentrifuge tube. The lysates were incubated on ice for 30 min and then centrifuged (14,000 × g, 10 min) at 4 °C, and the supernatants were saved for Western blotting or immunoprecipitation. Preparation of membrane and cytosol fractions was described previously (5).

**Immunoprecipitation and Western Blotting**—To analyze ErbB-4 in total cell lysates, ~1–2 μg of cell lysate were immunoprecipitated and underwent Western blotting or ~50 μg underwent blotting without immunoprecipitation. To assess ErbB-4 in cytosol and membrane fractions, equal volumes of each fraction representing equal numbers of cells were immunoprecipitated and then blotted.

To precipitate proteins, ~4 μg of ErbB-4 or presenilin 1 antibody was incubated (2 h at 4 °C) with lysates followed by a 1-h incubation with Protein A-Sepharose CL-4B. Immune complexes were washed three times with the same lysis buffer (TGH or mild TGH), resuspended in 1× Laemmli buffer, and boiled for 5 min. Subsequently, samples were electrophoresed in a 5.0% SDS-polyacrylamide gel and transferred to nitrocellulose membranes for Western blotting. Membranes were blocked by a 1-h incubation at room temperature in TBST buffer (0.05% Tween 20, 150 mM NaCl, 50 mM Tris, pH 7.4) containing 3% bovine serum albumin (for tyrosine phosphorylation detection) or 5% nonfat dry milk (for all others). Subsequently, ErbB-4 antisera or phospho-tyrosine antibody was added for 2 h at room temperature with shaking. Membranes were then washed thrice with TBST buffer, incubated with horseradish peroxidase-conjugated Protein A for 1 h, and after being washed with TBST buffer, visualized by ECL.

**Immunofluorescence Staining in Fixed Cells**—Cells grown on coverslips were fixed with methanol at −20 °C for 5 min. The cells were then rehydrated with PBS for 10 min and, after a 45-min blocking period using 10% goat serum (Sigma) in PBS, were incubated with C-18 ErbB-4 antibody for 45 min. After thorough washing (three times in PBS), secondary antibody Alexa Fluor™ 546 goat anti-rabbit IgG (H+L) conjugate (Molecular Probes) was added for 30 min. The cells were then mounted in Aqua Poly/Mount (Polysciences, Inc.). A Zeiss LSM 410 confocal microscope equipped with ×40 (1.3 numerical aperture) oil immersion objective lens, and the single fluorescent filter set for Alexa 546 (Molecular Probes) was used for visualization and recording images.

**RESULTS**

**Ligand Responsiveness of the ErbB-4 ΔTVV Mutation**—The carboxyl terminus of ErbB-4 encodes a PDZ domain recognition motif that has been demonstrated to facilitate interaction with PSD95, a multi-PDZ domain-containing protein that is highly expressed in neuronal cells (14, 15). However, the biological significance of ErbB-4 interaction with PDZ domains is not known.

To test the possible functional role of the PDZ domain binding motif in ErbB-4, the three carboxy-terminal residues that define this motif (16), were deleted to create the ErbB-4 mutant designated ΔTVV. We first tested by transient expression in COS7 cells the capacity of HRG to stimulate tyrosine phosphorylation of both WT ErbB-4 and the ΔTVV mutant. The results (Fig. 1A) demonstrate that both forms of ErbB-4 are activated by exogenous HRG. Subsequently, permanent cell lines expressing WT ErbB-4 or the ΔTVV mutant were obtained by transfection of NIH3T3 cells, which do not endogenously express any ErbB family members. In these cells, HRG also activated both receptor isoforms to approximately equivalent extents (Fig. 1B). Consistent with growth factor-dependent activation of both ErbB-4 species, HRG also activated Erk1 and Erk2 protein kinases when added to cells expressing WT ErbB-4 or the ΔTVV mutant (data not shown).

The above results show that loss of the PDZ domain recognition motif does not abrogate ligand-dependent receptor activation and by inference cell surface expression. This result is slightly in contrast to a previous report which concluded that the ErbB-4 PDZ domain recognition motif was required for maximal growth factor activation of this receptor (15).

**Influence of the ΔTVV Mutation on ErbB-4 Proteolytic Processing**—The ΔTVV mutation of ErbB-4 was evaluated to assess the potential role of the PDZ domain recognition motif in the proteolytic processing pathway, which requires the participation of at least two integral membrane proteases. The initial step in this pathway is the metalloprotease cleavage of ErbB-4, which produces an 80-kDa membrane-associated fragment (5). When cells expressing WT ErbB-4 or the ΔTVV mutant were treated with TPA, the 80-kDa fragment was produced at approximately the same rate from both receptor species for the first 60 min, as shown in Fig. 2. However, at a later time (3 h) the 80-kDa fragment generated in cells expressing the ErbB-4 ΔTVV mutant remained at a significant level, whereas the level of the fragment generated in cells expressing the wild-type receptor had significantly declined. These results indicate that whereas the ΔTVV mutation did not influence the metalloprotease cleavage of ErbB-4, the cell-associated fragment generated from the mutant receptor was significantly more metabolically stable.

One means by which the membrane-associated 80-kDa ErbB-4 fragment is metabolized is by γ-secretase cleavage. This cleavage converts the membrane-associated fragment, designated m80, to a cytosolic fragment, designated s80 (2). Therefore, the TPA-dependent formation of the m80 and s80 ErbB-4 fragments from the WT and ΔTVV ErbB-4 receptors were examined 30 min after the addition of the agonist. Detection of anti-ErbB-4 reactive bands in the membrane fraction (Fig. 3) shows that the full-length (180-kDa) WT ErbB-4 and
ΔTVV mutant proteins are degraded in the presence of TPA and that the m80 fragment is generated from each. However, the s80 ErbB-4 fragment is readily detected only in cells that express the WT receptor. Only a very low level of s80 is produced in cells expressing the ΔTVV mutant. After quantitating the s80 bands, it is estimated that production of this fragment is reduced by 90–95% in the ΔTVV mutant.

The above results indicate that introduction of the ΔTVV mutation selectively abrogates conversion by γ-secretase of the mutant m80 ErbB-4 fragment to the s80 fragment. γ-Secretase catalytic activity is generally considered to be a property of presenilins; however, this point remains unclear (17). Other substrates of γ-secretase, such as APP and Notch, have been found to co-precipitate with presenilins (PS1, PS2) (18–22).

A co-precipitation strategy was employed to ascertain whether presenilin associates with ErbB-4 and whether this is influenced by the receptor’s PDZ domain recognition motif. The results, as shown in Fig. 4 (left panel), demonstrate that when PS1 is immunoprecipitated from untreated cells expressing the WT ErbB-4 receptor, anti-ErbB-4 reactive proteins are detected representing the full-length ErbB-4 (180-kDa) and the 80-kDa ErbB-4 fragment. When TPA is added to these cells, however, the level of 80-kDa ErbB-4 fragment detected in the PS1 immunoprecipitate is greatly increased, as is the amount of 80-kDa fragment in these cells. Comparison of the amount of full-length ErbB-4 in untreated cells and 80-kDa fragment in TPA-treated cells suggests that PS1 associates preferentially with the 80-kDa fragment, which mostly represents the m80 γ-secretase substrate. In contrast, an almost undetectable level of ErbB-4 reactivity is found in PS1 immunoprecipitates from cells expressing the ΔTVV mutant. The data in the right panel show that in both cell types equal levels of full-length ErbB-4 are present and that in the presence of TPA the 80-kDa fragment is also detected at equivalent levels in both cell types. The results suggest that s80 is not generated from the m80 ΔTVV ErbB-4 mutant, because the latter fragment is unable to associate with PS1. The presence of PS2 in these cells was not detectable.

If the absence of a PDZ domain recognition motif prevents efficient γ-secretase cleavage of ErbB-4, then it would be expected that the ΔTVV mutant receptor would fail to be translocated to the nucleus after the addition of TPA. The data in Fig. 5 show that whereas TPA addition to cells expressing WT ErbB-4 receptor does provoke nuclear localization of ErbB-4 immunoreactivity, similar treatment of cells expressing the ΔTVV mutant reveals no nuclear ErbB-4 signal even if leptomycin B (23) is added to prevent nuclear export. The data additionally demonstrate that if leptomycin B is added but the cells are not stimulated with TPA, ErbB-4 reactive material is present in the nucleus of cells expressing the WT receptor but not in cells that express the ΔTVV mutant. This basal level of nuclear localized ErbB-4 is prevented in the cells expressing WT receptor by addition of the γ-secretase inhibitor Compound E (12).

Influence of ΔTVV Mutation on Cell Growth—When T47D mammary carcinoma cells are placed in serum-free medium, HRG-induced ErbB-4 cleavage leads to cell death in a manner that requires γ-secretase activity (2). Also, overexpression of the ErbB-4 cytoplasmic domain in COS cells results in cell death (8). Although a basal level of ErbB-4 cleavage exists in all cell systems, this was not sufficient to influence survival of the T47D cells. To investigate further the potential biological significance of basal ErbB-4 cleavage, the survival of the transfected NIH3T3 cells used in the experiments described herein was evaluated.

The data in Fig. 6 show that when cells expressing WT ErbB-4 or the ΔTVV mutant are placed in serum-free medium, the WT ErbB-4 cells initially survived and slightly increased in cell number, but by day 3 nearly all had died. In contrast, cells that express the ΔTVV mutant ErbB-4 survive under the same conditions, demonstrating that the ΔTVV mutation reduces the rate at which ErbB-4 is cleaved in vivo.


**FIG. 5.** PDZ domain recognition motif-dependent ErbB-4 nuclear localization. NIH 3T3 cells expressing WT ErbB-4 or ΔTVV were cultured on coverslips until 80% confluent and then incubated overnight in DMEM with 0.2% FBS (a, b, c, d), or with leptomycin B (10 ng/ml) (e, g), or with leptomycin B (LMB, 10 ng/ml) and compound E (CmpE E, 10 nM) (d, h) as indicated. TPA (100 ng/ml) was then added (b, f) for 90 min. All cells were then fixed and immunostained with C-18 ErbB-4 antibody for confocal microscopy as described under "Experimental Procedures." Bar, 25 μm, applies to each image.

**FIG. 6.** Influence of ΔTVV mutation on cell death. NIH 3T3 cells expressing WT ErbB-4 (○) or the ΔTVV mutant (□) were plated (~2 × 10^5 cells/well) in 12-well dishes. On the next day (day 0), the cells were washed with DMEM twice and cultured in serum-free DMEM. Cell numbers were determined at 24-h intervals thereafter, using a Coulter counter.

culture conditions for at least 4 days. This result indicates that cells expressing the γ-secretase cleavable WT ErbB-4 are sensitive to cell death under these conditions, but the ΔTVV mutant does not produce a signal that provokes cell death. This also suggests that in these NIH3T3 cells, basal ErbB-4 cleavage is sufficient to provoke a cell response.

To confirm that γ-secretase activity is necessary for this growth response, the experiment was repeated in the presence of Compound E, a potent γ-secretase inhibitor (12). The cells were plated as described in Fig. 6, and cell numbers were determined 3 days later (Table I). The results demonstrate that only 14% of the cells expressing the WT ErbB-4 survived under these conditions, whereas 88% of the cells expressing the ΔTVV mutant survived. The addition of Compound E almost completely prevented cell death in cells expressing the WT ErbB-4 receptor but did not significantly alter the response of cells that express the ΔTVV mutant.

**TABLE I**

| Additions       | Final cell number (×1000) | WT     | ΔTVV   |
|-----------------|--------------------------|--------|--------|
| None            | 27.3 ± 11.4              | 176.7 ± 12.3 |
| Compound E      | 283.7 ± 32.9             | 153.7 ± 11.5 |

**DISCUSSION**

The major conclusion of the experimental results presented in the manuscript is that PDZ domains have a central role in the mechanism by which ErbB-4 is recognized and processed by γ-secretase activity. This proteolytic step seems to involve intramembranous cleavage of ErbB-4 and results in the release of the receptor’s cytoplasmic domain (s80) into the cytosol and nucleus (2).

The immediate substrate for γ-secretase activity is not the full-length ErbB-4 but rather a membrane-associated fragment (m80) that is derived from the native receptor by metalloprotease-mediated cleavage of the receptor ectodomain (2). The steps in this proteolytic pathway for ErbB-4 are analogous to those described for the proteolytic processing of Notch, a non-tyrosine kinase receptor, and APP, a nonreceptor transmembrane molecule. The intramembranous cleavage of all three substrates requires γ-secretase activity. However, the cleavage sites in Notch and APP are dissimilar in sequence and relative location within the transmembrane domain (17). Hence, γ-secretase recognition is not thought to depend on substrate primary sequence information, as is the case with many other proteases. The transmembrane sequence of ErbB-4 is unlike that of Notch or APP.

The data presented herein show that the carboxyl-terminal PDZ domain recognition motif of ErbB-4 is required for γ-secretase cleavage of the ErbB-4 m80 fragment. This motif is also necessary for association of PS1 with the m80 ErbB-4 fragment. These results imply that the target of this ErbB-4 motif plays an important role in mediating intramembranous cleavage of ErbB-4. Others have identified PSD95 as one target of the ErbB-4 carboxy-terminal sequence (14, 15). PSD95, which is highly expressed in neuronal cells, contains three PDZ domains, two of which recognize ErbB-4. In neuronal tissue PSD95 functions to organize specialized complexes of transmembrane proteins (16). In the non-neuronal cells used in the experiments described herein, we have been able to detect PSD95 family members in ErbB-4, but not PS1, immunoprecipitates (data not shown).

Interestingly, the carboxyl terminus of the Cooh-terminal fragment of PS1 also contains a PDZ domain recognition sequence, and PDZ domain-containing-proteins that recognize PS1 through this motif have been reported (22, 24). Hence, it seems plausible to suggest that ErbB-4 association with γ-secretase involves PDZ domain-containing proteins acting as a scaffold to bridge the two molecules. Both APP and Notch have also been shown to associate with PS1 using co-precipitation methodology. However, the associations are not known to be direct and may involve other molecules. In the APP/PS1 association, evidence exists that a PDZ domain-containing protein interacts by a PDZ domain with PS1 and by another domain with APP (22). Because PDZ domain-containing proteins often multimerize, it is possible that multiple proteins...
having PDZ domains could facilitate ErbB-4 association with \( \gamma \)-secretase activity. Alternatively, it is possible that mutation of the ErbB-4 PDZ domain recognition motif alters the cell surface trafficking of ErbB-4 and prevents \( \gamma \)-secretase cleavage.

Acknowledgments—We thank Dr. T. Golde for Compound E, Dr. M. Yoshida for leptomycin B, and Dr. M. Kraus for ErbB-4 antibody.

REFERENCES

1. Yarden, Y., and Sliwkowski, M. X. (2001) *Nat. Rev. Mol. Cell. Biol.* 2, 127–137
2. Ni, C.-Y., Murphy, M. P., Golde, T. E., and Carpenter, G. (2001) *Science* 294, 2179–2181
3. De Strooper, B., Annaert, W., Cupers, P., Saftig, P., Craessaerts, K., Mumm, J. S., Schröter, E. H., Schrijvers, V., Wolfe, W. S., Ray, W. J., Goate, A., and Kopan, A. (1999) *Nature* 398, 518–522
4. Selkoe, D. J. (2001) *Proc. Natl. Acad. Sci. U. S. A.* 98, 11039–11041
5. Vechi, M., Baulida, J., and Carpenter, G. (1996) *J. Biol. Chem.* 271, 18989–18995
6. Zhou, W., and Carpenter, G. (2000) *J. Biol. Chem.* 275, 34737–34743
7. Rio, C., Buxbaum, J. D., Peschen, J. J., and Corfas, G. (2000) *J. Biol. Chem.* 275, 10379–10387
8. Lee, H. J., Jung, K. M., Huang, Y. Z., Bennett, L. B., Lee, J. S., Mei, L., and Kun, T. W. (2002) *J. Biol. Chem.* 277, 6318–6323
9. Lin, S. Y., Makino, K., Xia, W., Matin, A., Wen, Y., Kwong, K. Y., Bourguignon, L., and Hung, M. C. (2001) *Nat. Cell Biol.* 3, 802–808
10. Offterdinger, M., Schüer, C., Weipoltshammer, K., and Grunt, T. W. (2002) *J. Cell Biol.* 157, 929–940
11. Reilly, J. F., and Maher, P. A. (2001) *J. Cell Biol.* 152, 1307–1312
12. Seiffert, D., Bradley, J. D., Rominger, C. M., Rominger, D. H., Yang, F., Meredith, J. E., Jr., Wang, Q., Roach, A. H., Thompson, L. A., Spitz, S. M., Higak, J. N., Prakash S. R., Combs, A. F., Copeland, R. A., Arneric S. P., Hartig, P. R., Robertson, D. W., Cordell, H., Stern, A. M., Olson, R. E, and Robert Zaczek, R. (2000) *J. Biol. Chem.* 275, 34086–34091
13. Baulida, J., Kraus, M. H., Alimandi, M., Di Fiore, P. P., and Carpenter, G. (1996) *J. Biol. Chem.* 271, 5251–5257
14. Garcia, R. A., Vasudevan, K., and Buonanno, A. (2000) *Proc. Natl. Acad. Sci. U. S. A.* 97, 3596–3601
15. Huang, Y.-Z., Won S., Ah, D. W., Wang, Q., Tanowitz, M., Du, Q. S., Pelkey, K. A., Yang, D. J., Xiong, W. C., Sailer, M. W., and Mei, L. (2000) *Neuron* 26, 443–455
16. Hung, A. Y., and Sheng, M. (2002) *J. Biol. Chem.* 277, 5699–5702
17. Sisodia, S. S., and St. George-Hyslop, P. H. (2002) *Nat. Rev. Neurosci.* 3, 281–290
18. Xia, W., Zhang, J., Perez, R., Koo, E. H., and Selkoe, D. J. (1997) *Proc. Natl. Acad. Sci. U. S. A.* 94, 8208–8213
19. Weidemann, A., Paliga, K., Durrwang, U., Czech, C., Evin, G., Masters, C. L., and Beyreuther, K. (1997) *Nat. Med.* 3, 328–332
20. Ray, W. J., Yao, M., Nowotny, P., Mumm, J., Zhang, W., Wu, J. Y., Kopan, R., and Goate, A. M. (1999) *Proc. Natl. Acad. Sci. U. S. A.* 96, 3263–3268
21. Ray, W. J, Yao, M., Mumm, J., Schröter, E. H., Saftig, P., Wolfe, M., Selkoe, D. J., Kopan, R., and Goate, A. M. (1999) *J. Biol. Chem.* 274, 36801–36807
22. Lau, K. F., McLoughlin, D. M., Stauden, C., and Miller, C. C. (2000) *Mol. Cell. Neurosci.* 16, 557–565
23. Ossareh-Nazari, B., Bachelerie, F., and Dargenmet, C. (1997) *Science* 278, 141–144
24. Xu, X., Shi, Y., Wu, X., Gambetti, P., Sui, D., and Cui, M. Z. (1999) *J. Biol. Chem.* 274, 32543–32546